Our mission is to provide accurate and useful health information. If we determine that our content contains confusing, misleading or inaccurate information, we will revise the content. This policy applies to all original content.
- In Primary biliary cholangitis - Diagnosis and treatment - Mayo Clinic: Ocaliva (obeticholic acid) has been removed from the list of medicines used to treat primary biliary cholangitis. On September 11, 2025, Intercept Pharmaceuticals voluntarily withdrew Ocaliva from the U.S. market following a request from the U.S. Food and Drug Administration (FDA). The FDA also placed a clinical hold on all U.S. trials involving obeticholic acid.
- In Coronavirus disease 2019 (COVID-19), the 2024-2025 COVID-19 vaccine information has been replaced with 2025-2026 COVID-19 vaccine information.
September 27, 2025
